Drugs Xagena
The FDA ( U.S. Food and Drug Administration ) has approved Larotrectinib ( Vitrakvi ), the first oral TRK inhibitor. The approval is for the treatment of adult and pediatric patients with solid tumor ...
The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Rozlytrek ( Entrectinib ), a treatment for adult and adolescent patients whose cancers have the specific genetic defec ...
The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi ( Larotrectinib ). The drug is indicated for the treatment of a ...
The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Vitrakvi ( Larotrectinib ), a treatment for adult and pediatric patients whose cancers have a specific genetic feature ...
